Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The reporting period covers the month of February 2026, with the specific transaction date being February 23, 2026. The filing was submitted on February 24, 2026.
Key Financial Metrics and Transaction Details
The filing details a share repurchase executed under an existing buyback programme via a non-discretionary agreement with BNP Paribas SA.
- Shares Purchased (Feb 23): 462,000 ordinary shares.
- Price Range: Lowest price paid was 2,184.00 GBp; highest price paid was 2,213.00 GBp.
- Volume-Weighted Average Price (VWAP): 2,200.95 GBp.
- Accumulated Purchases (Since Feb 17): 2,229,000 ordinary shares.
- Treasury Shares Held: 242,120,094 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,074,032,332 ordinary shares.
- Treasury Voting Rights: 5.94% of total voting rights.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury shares following the repurchase of 462,000 shares on February 23, 2026. This transaction is part of a continuous buyback programme initiated on February 17, 2026. The filing does not provide comparative financial data (revenue, profit, cash flow) for the period, as it is a transaction report rather than a financial results statement.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in GSK's Annual Report on Form 20-F for 2024 and Q4 Results for 2025. No specific new risks or contingencies were disclosed in this document.
Investor Verification Checklist
- Verify the total remaining authorization under the existing buyback programme to assess future repurchase capacity.
- Confirm the impact of the 5.94% treasury holding on earnings per share (EPS) calculations and voting rights thresholds.
- Review the "Risk Factors" section of the 2024 Form 20-F and 2025 Q4 results referenced in the cautionary statement for context on potential financial variances.
- Monitor subsequent filings for the completion status of the non-discretionary agreement with BNP Paribas SA.